Company News

You are here:

Home
News

PharmaJet and Diomics partner on SARS-CoV-2 immune response monitoring

GOLDEN, Colo. — November 17, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Tropis^® Needle-free Injection System will be used by Diomics, a San Diego-based biotech company, to deliver a biopolymer to detect the formation of an immune response to a SARS-CoV-2 protein. The company was awarded over $2 million by the Department of Defense to accelerate testing of its Diocheck^™ system and is expected to begin human clinical trials in December 2020.

The Diocheck SARS-CoV-2 Visual Immune Response Indicator provides a simple, universal way to continually monitor a person’s immune response status to COVID-19 over an extended period of time … Details

University of Cambridge receives Multi-million Dollar Funding for Clinical Trial using PharmaJet’s Needle-free System to Deliver Vaccine to Prevent COVID-19

GOLDEN, Colo. — October 27, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial. The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently received multi-million dollar funding from the UK government to move forward with a clinical trial. Preparations for the clinical trial are well underway and the trial will begin as soon as possible. Details

PharmaJet’s Needle-free System to be used in Australian Clinical COVID-19 Trial

GOLDEN, Colo. — October 6, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Stratis^® Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial in Australia. The DNA-based vaccine COVIGEN was developed by French-Thai pharmaceutical company BioNet and Melbourne-based biotech Technovalia. The Phase 1 trial is a joint collaboration between Australia’s most experienced vaccine trial sites including the University of Sydney, the Telethon Kids Institute in Perth, the University of Adelaide, the Vax4COVID alliance, and with multi-million dollars financial support of Australia’s Medical Research Future Fund. Details

PharmaJet Announces Addition of Melissa Malhame as VP Business Development

GOLDEN, Colo. — September 29, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Melissa Malhame, has joined the leadership team as Vice President, Business Development. Ms. Malhame is a global business executive with over 25 years of experience in business development, strategic sales, and marketing for major vaccine providers such as Gavi, Dynavax and Merck, as well as supporting global health investments in new vaccine candidates and expanding access to existing vaccines. In this role she will be leading business development, sales, and marketing for the Pharmajet organization. Details

International Pharmaceutical Development Consortium to partner with PharmaJet for delivery of COVID-19 DNA Vaccine, GX-19

GOLDEN, Colo. — September 15, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Stratis® Needle-free Injection System will be used to deliver a novel DNA vaccine against COVID-19 (GX-19) which is being developed by an international consortium led by Genexine, a leading biotherapeutics company headquartered in South Korea. The consortium also includes the International Vaccine Institute (IVI), Binex, GenNBio, Korea Advanced Institute for Science and Technology, and Pohang University of Science and Technology. Details

PharmaJet and Abnova partner to develop and deliver COVID-19 mRNA Vaccine using Needle-free Injection technology

GOLDEN, Colo. — May 19, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world’s largest antibody manufacturer, based in Taiwan.

Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate.

Details

PharmaJet Announces Executive Leadership Changes

GOLDEN, Colo. — April 28, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced the appointment of Chris Cappello to President and Chief Executive Officer. Chris replaces Ron Lowy, who was appointed Executive Chairman of the board.

Ron Lowy, Executive Chairman, PharmaJet Inc. said, “ In the 10 years that Chris has worked for PharmaJet he has shown the ability to lead the organization and expand on our important collaborations with groups such as the US federal government, the World Health Organization, multiple pharmaceutical partnerships…

Details

PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 Vaccine

GOLDEN, Colo. — April 14, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Tropis^® Needle-free injection system will be used to deliver a COVID-19 vaccine being developed by Immunomic Therapeutics, Inc. (ITI). ITI is a clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms using the body’s natural biochemistry to generate a broad immune response. The vaccine candidate against COVID-19 will leverage their investigational UNiversal Intracellular Targeted Expression (UNITE^TM) platform. Details

Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using its Investigational UNITE Platform

ROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO — April 09, 2020 — Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of the novel coronavirus disease caused by SARS-Cov-2 coronavirus. Details

PharmaJet Announces Appointment of Pharmaceutical Executive Dr. Marie Mazur to the Board of Directors

GOLDEN, Colo. — March 25, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Dr. Marie Mazur, has been appointed to its Board of Directors. Dr. Mazur is a global business executive with over 30 years of experience growing revenue and profits for major vaccine and pharmaceutical companies.

Ron Lowy, Executive Chairman, PharmaJet Inc. said, “we are very pleased to welcome Dr. Mazur to the PharmaJet Board of Directors." Details